Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis

Miyoshi, Arina; Kameda, Hiraku; Nagai, So; Nakamura, Akinobu; Miya, Aika; Takase, Takahiro; Atsumi, Tatsuya; Miyoshi, Hideaki

Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis

Miyoshi, Arina; Kameda, Hiraku; Nagai, So et al.

Journal of Diabetes Investigation, 2021, 12(7), 1293-1300

Permalink : https://hdl.handle.net/2115/82880

このアイテムのアクセス数:494件（2026-08-17 11:13 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
JDI 12 1293-1300	pdf	383 KB	505

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/82880
タイトル	Beneficial effects of switching to denosumab from bisphosphonates or selective estrogen receptor modulators in postmenopausal women with type 2 diabetes and osteopenia/osteoporosis
著者	Miyoshi, Arina ; Kameda, Hiraku ; Nagai, So ; Nakamura, Akinobu ; Miya, Aika ; Takase, Takahiro ; Atsumi, Tatsuya ; Miyoshi, Hideaki
著者名 Miyoshi, Arina
e-Rad_Researcher 20826127 著者名 Kameda, Hiraku
e-Rad_Researcher 70507590 著者名 Nagai, So
e-Rad_Researcher 70552420 著者名 Nakamura, Akinobu
著者名 Miya, Aika
著者名 Takase, Takahiro
e-Rad_Researcher 20301905 著者名 Atsumi, Tatsuya
e-Rad_Researcher 30360902 著者名 Miyoshi, Hideaki
言語	英語
キーワード	Denosumab
	Osteoporosis
	Type 2diabetes
発行日	2021-07-08
出版者	John Wiley & Sons
収録物名	Journal of Diabetes Investigation
巻(号)	12(7)
ページ	1293-1300
抄録	Aims/Introduction Patients with type 2 diabetes mellitus have a higher bone fracture risk than patients without diabetes. Although denosumab (Dmab) is a potent bone resorption inhibitor, its efficacy in patients with type 2 diabetes mellitus has not been elucidated. In this study, we investigated the effects of switching to Dmab from bisphosphonates (BP) or a selective estrogen receptor modulator (SERM) in postmenopausal type 2 diabetes mellitus patients. Materials and Methods This was a three medical institutions, prospective, observational study for postmenopausal patients with type 2 diabetes mellitus whose T‐score of femoral neck or lumbar spine bone mineral density was under -1.0 standard deviation, even after >6 months of BP or SERM administration. After obtaining consent, participants were treated for osteopenia/osteoporosis by either continuing BP (BP‐BP group)/SERM (SERM‐SERM group), or by switching to Dmab (BP‐Dmab or SERM‐Dmab groups). Changes in bone mineral density and bone metabolism marker levels were evaluated after 6 months. Results A total of 48 patients were included in this study, and each group comprised 12 patients. No significant difference existed in baseline characteristics among the groups. The average age and glycated hemoglobin were 71 ± 8 years and 7.2 ± 0.9%, respectively. In the SERM‐Dmab group, lumbar spine bone mineral density was significantly increased by 5.0% compared with the SERM‐SERM group (P < 0.04). Serum bone‐specific alkaline phosphatase and tartrate‐resistant acid phosphatase 5b were significantly decreased in the BP‐Dmab and SERM‐Dmab groups compared with the BP‐BP and SERM‐SERM groups, respectively. Conclusions Switching to Dmab from BP or SERM is beneficial to prevent osteoporosis progression in postmenopausal patients with type 2 diabetes mellitus patients.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution-NonCommercial 4.0 International
PISSN	2040-1116
EISSN	2040-1124
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1111/jdi.13458